
Wockhardt Limited has informed the Exchange regarding a press release dated October 16, 2024, titled - Wockhardt files fast-acting Insulin Aspart injection (ASPARAPIDTM) with DCGI; strengthens commitment to diabetes management .
Filed with NSE · · 3 pages · English
Wockhardt Limited has submitted a press release regarding the filing of its fast-acting insulin Aspart injection with the Drugs Controller General of India. This filing highlights Wockhardt's commitment to diabetes management amid the rising prevalence of diabetes in India and globally. The product aims to enhance quality and accessibility for patients, with plans for various delivery formats. Wockhardt is also developing additional diabetes care solutions to strengthen its portfolio.
Written by 6ix AI from the company’s filing. How 6ix writes summaries

Wockhardt Limited has informed the Exchange regarding a press release dated October 16, 2024, titled - Wockhardt files fast-acting Insulin Aspart injection (ASPARAPIDTM) with DCGI; strengthens commitment to diabetes management .
Follow Wockhardt into a list and get an email when it puts out news.
Follow Wockhardt